NAD+ (Nicotinamide Adenine Dinucleotide) Testing
Central redox cofactor for cellular metabolism, DNA repair, and sirtuin activity.
Mechanism of action
Nicotinamide adenine dinucleotide is the central redox cofactor for cellular energy metabolism. NAD+/NADH ratio modulates sirtuin (SIRT1-7) activity, PARP-mediated DNA repair, and CD38-driven immune signaling. Injectable and IV NAD+ research seeks to address the decline in tissue NAD+ pools observed with aging.
Research areas
- ●Cellular aging and sirtuin biology
- ●Mitochondrial dysfunction
- ●Neurodegenerative disease research
- ●Addiction recovery (anecdotal)
Dosing in the literature
Research IV protocols use 250–1500 mg over 2–4 hours. SC and intranasal forms exist but lack rigorous bioavailability data.
For research/informational purposes only — not medical advice.
What we test on NAD+ (Nicotinamide Adenine Dinucleotide)
Stability-indicating HPLC method (ion-pair RP) separating NAD+, NADH, nicotinamide, and ADP-ribose. Quantitation by external standard. Endotoxin and sterility mandatory for any injectable.
- ✓RP-HPLC purity
- ✓LC-MS identity
- ✓Stability indicating method (NAD+)
Common impurities & failure modes
- Nicotinamide (degradation product)
NAD+ → nicotinamide hydrolysis happens rapidly in solution; quantify both to assess true active NAD+ at injection time, not just at receipt.
- NADH
Reduced form; presence depends on storage conditions.
- ADP-ribose
From CD38-mediated cleavage; appears in aged material.
- Heavy metals from synthesis
ICP-MS screen recommended; injectable spec <10 ppm total.
Storage & stability
−20 °C lyophilized; reconstituted should be used within 24 hours and protected from light.